

Draft Guidance on Chlorpromazine Hydrochloride

This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active ingredient: Chlorpromazine Hydrochloride

Form/Route: Tablet; Oral

Recommended study: 3 Studies

1. Type of study: Fasting
Design: Single-dose, crossover *in-vivo*
Strength: 100 mg
Subjects: Healthy males and nonpregnant females, general population
Additional Comments:

2. Type of study: Fed
Design: Single-dose, crossover *in-vivo*
Strength: 100 mg
Subjects: Healthy males and nonpregnant females, general population
Additional Comments: Please refer to the Amantadine Hydrochloride Tablet Draft Guidance for additional information regarding fed studies.

3. Type of study: Fasting
Design: Single-dose, crossover *in-vivo*
Strength: 25 mg
Subjects: Healthy males and nonpregnant females, general population
Additional Comments:

Analytes to measure (in appropriate biological fluid): Chlorpromazine and its active metabolite, 7-hydroxychlorpromazine, in plasma.

Bioequivalence based on (90% CI): Chlorpromazine

Please submit data for the active metabolite to support bioequivalence of the test products to the reference products. For the metabolite, the following data should be submitted: individual and mean concentrations, individual and mean pharmacokinetic parameters, and geometric means and ratios of means for AUC and C_{\max} .

Waiver request of in-vivo testing: 50 mg and 200 mg based on (i) acceptable bioequivalence studies on the 100 mg strength, (ii) acceptable in-vitro dissolution testing of all strengths, and (iii) proportional similarity of the formulations across all strengths.

Waiver request of in-vivo testing: 10 mg based on (i) acceptable bioequivalence studies on the 25 mg strength, (ii) acceptable in-vitro dissolution testing of both strengths, and (iii) proportional similarity of the formulations across both strengths.

Please refer to the Mirtazapine Tablet Draft Guidance for additional information regarding waivers of in-vivo testing

Dissolution test method and sampling times:

Please note that a **Dissolution Methods Database** is available to the public at the OGD website at <http://www.accessdata.fda.gov/scripts/cder/dissolution/>. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.